APPICATION OF GALECTIN3 , A NOVEL IMMUNOSTAIN, IN PROSTATIC CARCINOMA TO ASSESS ITS PATTERN OF EXPRESSION AND FUTURE POTENTIAL- CONDUCTED AS A TOOL OF MINI RESEARCH PROJECT

Abstract

Carcinoma of prostate is the commonest type of cancer found in males of developed countries and is responsible for large number of cancer related deaths and signicant morbidity .Gleason’s grade and PSA level play pivotal role in decision making in the management of patients with prostate cancer. By modulating various aspects of tumour progression, Galectin 3 is emerging as a potential guardian of tumour microenvironment and studies indicate that it has important regulatory role in pathogenesis and progression of prostate cancer. An observational cross sectional study was undertaken in the department of pathology of a tertiary care hospital in East India, of 6 months duration. Twenty nine samples diagnosed as acinar adenocarcinoma of prostate were taken by systematic random sampling as per the inclusion-exclusion criteria from the received specimens in the department and immuno-histochemical examination was done on the selected samples using monoclonal antibody against Galectin3 after obtaining thin sections from formalin xed parafn embedded blocks and retrieval of antigen. The data was interpreted by light microscopy using a semi-quantitative method with respect to prexed parameters and statistical analysis was done using SPSS version 25. Based on the prexed cut off, 20.7% of total cases have shown positive expression of galectin3. Mainly the tumours with lower Gleason’s grade have shown positive expression of this marker (62.5% of grade group 1 and 16.6% of grade group 2). None of the cases belonging to grade group 3, 4 or 5 have shown even minimal positivity. Positive expression of galectin3 appeared to decrease with progression of Gleason’s grade and this association was found to be statistically signicant. However, no signicant association has been found between expression of this marker and percentage of the positive cores or the degree of maximum linear positivity.